FIRE AND ICE II Trial Pilot

NCT ID: NCT03706677

Last Updated: 2023-11-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

69 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-05

Study Completion Date

2023-04-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The FIRE AND ICE II Trial (Pilot) is the pilot phase of a prospective, randomized, single-blinded, multi-center, interventional post-market clinical trial, comparing efficacy and safety of isolation of the pulmonary veins (PVI) using a Cryoballoon catheter or radiofrequency ablation with a ThermoCool® Smarttouch® catheter in subjects with persistent atrial fibrillation (AF).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

60 patients with persistent AF will be randomized 1:1 between Cryoballoon ablation and Radiofrequency ablation in the FIRE AND ICE II Trial Pilot at 5 clinical sites in Europe.

The data collected within the pilot phase will be reviewed and a decision on extending the trial with an extended number of patients and sites as main phase will be taken.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Persistent Atrial Fibrillation Atrial Arrhythmia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomization 1:1 between Cryoballoon ablation and Radiofrequency ablation
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
Single-blinded; participants will be blinded to the treatment group. Investigators will be blinded on study specific diagnostics used in the trial; Endpoint Review Committee will be blinded to the treatment group.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CRYO group

Within the CRYO arm the ablation will be performed using the Arctic Front Advance Cardiac CryoAblation Catheter, including next generation systems as applicable and approved by Medtronic for the trial.

Intervention performed: Cryoballoon ablation; Cryoballoon (Arctic Front Advance Cryoballoon)

Group Type ACTIVE_COMPARATOR

Cryoballoon (Arctic Front Advance Cryoballoon)

Intervention Type DEVICE

Ablation using a Cryoballoon catheter (Arctic Front Advance Cryoballoon Cardiac Ablation Catheter)

RF group

Within the RF arm the ablation will be performed using a catheter out of the ThermoCool Smarttouch catheter family, including next generation contact force systems as applicable.

Intervention performed: Radiofrequency ablation; Radiofrequency Catheter (ThermoCool Smarttouch)

Group Type ACTIVE_COMPARATOR

Radiofrequency Catheter (ThermoCool Smarttouch)

Intervention Type DEVICE

Ablation using a Radiofrequency ablation catheter (ThermoCool Smarttouch catheter)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cryoballoon (Arctic Front Advance Cryoballoon)

Ablation using a Cryoballoon catheter (Arctic Front Advance Cryoballoon Cardiac Ablation Catheter)

Intervention Type DEVICE

Radiofrequency Catheter (ThermoCool Smarttouch)

Ablation using a Radiofrequency ablation catheter (ThermoCool Smarttouch catheter)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documentation of symptomatic persistent AF (following the European Society of Cardiology (ESC) guideline 2016) defined as: Persistent AF - AF that lasts longer than 7 days, including episodes that are terminated by cardioversion, either with drugs or by direct current cardioversion, after 7 days or more
* Date of first diagnosis of persistent AF within the last 12 months preceding the date of screening
* Documented treatment failure or intolerance of at least one Class I or Class III antiarrhythmic drug

Exclusion Criteria

* Known pre-existing hemi-diaphragmatic paralysis
* Prior left atrial ablation or surgical procedure (including left atrial appendage closures)
* History of right atrial flutter, not ablated prior to enrollment
* Any cardiac surgery, myocardial infarction, percutaneous coronary intervention or coronary artery stenting which occurred within the 3 months before the eligibility assessment
* Unstable angina pectoris
* Primary pulmonary hypertension
* Any condition contraindicating chronic anticoagulation
* Any cerebral ischemic event (stroke or transient ischemic attack \[TIA\]) which occurred within the 6 months before the consent date
* Presence of any cardiac prosthetic valves
* Long-standing persistent AF lasting for ≥ 1 year (even when it is decided to adopt a rhythm control strategy)
* New York Health Association (NYHA) class III or IV heart failure and/or documented left ventricular ejection fraction (LVEF) \< 40% measured by acceptable cardiac testing (e.g. TTE)
* Acute cardiac condition, including endocarditis, pericarditis or pericardial effusion
* Presence or likely implant of a permanent pacemaker, biventricular pacemaker or any type of implantable cardiac defibrillator (with or without biventricular pacing function) within 12 months
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

genae associates (CRO), Antwerp, Belgium

UNKNOWN

Sponsor Role collaborator

King's College London

OTHER

Sponsor Role collaborator

Deutsches Herzzentrum Muenchen

OTHER

Sponsor Role collaborator

Medtronic Cardiac Rhythm and Heart Failure

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Karl-Heinz Kuck, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Asklepios St. Georg, Hamburg

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinique Pasteur Toulouse

Toulouse, Cedex 3, France

Site Status

Herz-Zentrum Bad Krozingen

Bad Krozingen, , Germany

Site Status

Cardioangiologisches Centrum Bethanien CCB

Frankfurt am Main, , Germany

Site Status

Asklepios St. Georg

Hamburg, , Germany

Site Status

Universitätsklinikum Schleswig-Holstein / Campus Lübeck

Lübeck, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MDT17037

Identifier Type: -

Identifier Source: org_study_id